Hemostasis and Thrombosis Research Program

The Hemostasis and Thrombosis Research Program has one goal: to provide cutting edge and dedicated comprehensive services for the evaluation and treatment of children with bleeding or clotting disorders in a comfortable environment.  Additionally, patients with bleeding disorders are also cared for by the UNC Hemophilia and Thrombosis Center, a multi-disciplinary team, made up of physicians, nurse coordinators, social worker, geneticist, and physical therapists. For more information about the University of North Carolina’s Hemophilia and Thrombosis Center, please click here

Conditions treated include:

  • Bleeding disorders such as Hemophilia, von Willebrand Disease, Platelet Function Defects
  • Rare Factor Deficiencies
  • Thrombosis
  • Other Coagulation and Bleeding Disorders
  • Immune Thrombocytopenia Purpura

Currently Open Clinical Trails 

DiagnosisSponsorStudy Title with ClinicalTrails.Gov Link
Hemophilia A Genentech HAVEN-4 evaluating emicizumab/ACE910 in hemophilia A patients with or without inhibitors against factor VIII (Q4W)
Hemophilia A or B Alnylam ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients with Hemophilia A or B, with Inhibitory Antibodies to Factor VIII or IX
Hemophilia A or B Alnylam ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, Without Inhibitory Antibodies to Factor VIII or IX
Hemophilia B Biogen, Swedish Orphan Biovitrum B-Natural : The Natural History Study of Factor IX Treatment and Complications